NasdaqGM:IRONBiotechs
Assessing Disc Medicine (IRON) Valuation After FDA Review Delay And Heightened Regulatory Focus
Disc Medicine (IRON) is back in focus after the FDA extended its review of the company’s experimental therapy bitopertin, citing questions around trial data integrity and potential abuse risk.
See our latest analysis for Disc Medicine.
Those FDA questions and the recent executive hire have played out against a softer tape, with the 7 day share price return of 9.23% and 90 day share price return of 18.63% contrasting with a 1 year total shareholder return of 21.78% and a very large 3 year...